Meda, which MYL attempted to acquire in 2014, sells specialty drugs, branded generics, and OTC products in 150 countries. Meda is a reasonable (but smaller) alternative to PRGO, which MYL attempted to acquire in 2015.
The nominal deal value is $9.9B, including the assumption of $2.7B in debt.
MYL fell 9% in AH trading, although some of the drop may be attributable to MYL’s tepid guidance for 2016 non-GAAP EPS of $4.85-$5.10 (#msg-120453066).
Market Data 
Markets 
AI
